戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ression, associated with a decrease in serum paraprotein.
2  was positively correlated with the level of paraprotein.
3 ecreted by the tumor cells and the IgG serum paraprotein.
4  monoclonal antibodies, immune complexes and paraproteins.
5 c method to identify the cognate antigens of paraproteins.
6 rden of clonal plasma cells that produce the paraproteins.
7 s from all patients with HSP90-SUMO1-binding paraproteins.
8 s (1.9 years) than patients with IgA and IgG paraproteins (2.3 and 2.5 years, respectively) (P < .001
9 tinuum that requires the presence of a serum paraprotein and differs in severity of skin lesions, ext
10       We have prospectively evaluated serial paraprotein and serum free light chain (FLC) measurement
11                                        Serum paraproteins and/or light chains or bone marrow biopsy d
12  experienced a greater than 50% reduction in paraprotein, and four (17%) of 24 patients entered compl
13  of 18 cases, the serum contained benign IgM paraproteins, and in four of these cases at least two Ig
14        Plasma cells producing high levels of paraprotein are dependent on the unfolded protein respon
15  increase in FLC both alone and with a whole paraprotein, as a result of a significantly shorter surv
16 pathy, multifocal motor neuropathy, and some paraprotein-associated demyelinating neuropathies.
17                                              Paraprotein-associated neuropathies are a diverse group
18                                              Paraproteins can cause a remarkably diverse set of patho
19 relationship between SFLCR normalization and paraprotein clearance.
20 onic ataxic neuropathy, ophthalmoplegia, IgM paraprotein, cold agglutinins and disialosyl antibodies.
21                                We found that paraproteins from a proportion of European, African-Amer
22  sumoylated and screened for reactivity with paraproteins from MGUS, MM, and WM patients.
23                       E-MAP analysis of 2 MM paraproteins identified human cytomegalovirus (HCMV) as
24 ls in SCID-hu mice produced human monoclonal paraprotein (immunoglobulin M [IgM] and/or kappa or lamb
25  resulted in a greater than 25% reduction in paraprotein in 67% of patients, 13 patients (54%) experi
26 otein electrophoresis showed multiple clonal paraproteins in 4 of 5 cases.
27 chains (FLCs) are the most commonly detected paraproteins in chronic lymphocytic leukemia (CLL).
28 In three patients, all of whom had IgG-kappa paraproteins in their sera, the Abs were IgG-kappa.
29 in bands (APB), distinct from the presenting paraprotein, in 550 patients receiving high-dose therapy
30 physiology and the differential diagnosis of paraprotein-induced crystalline nephropathy.
31 was one complete response and a reduction in paraprotein levels and/or marrow plasmacytosis in eight
32                            Reductions in the paraprotein levels were apparent within two months in 78
33 TGM1 cells, reduced serum myeloma-associated paraprotein levels, and better preservation of bone mine
34 th IgM AL amyloidosis have a significant IgM paraprotein (median, 10 g/L), less frequent lambda light
35 de in explaining the molecular mechanisms of paraprotein-mediated kidney injury.
36  Best responses of at least 25% reduction in paraprotein occurred in 17 (71%) of 24 patients (90% con
37 ented with a whole paraprotein relapsed with paraprotein only (PO) and "FLC escape," respectively.
38 ectrophoresis (IFE), could be due to altered paraprotein production by the malignant plasma cell clon
39 cytic infiltrate in bone marrow (BM) and IgM paraprotein production.
40 4 of 520 patients who presented with a whole paraprotein relapsed with paraprotein only (PO) and "FLC
41 lantation in the management of patients with paraprotein-related kidney disease continues to evolve.
42                     We first reconstruct the paraprotein's epitope by analyzing the peptides that str
43              We observed inhibition of serum paraprotein secretion, inhibition of tumor growth, and i
44 SUMO1 carriers produced HSP90-SUMO1-specific paraproteins, suggesting that sumoylated HSP90 promotes
45 we identified a posttranslationally modified paraprotein target (paratargs) in monoclonal gammopathie
46 es reduced tumor load assessed by monoclonal paraprotein titers, prevented splenomegaly, limited deve
47     Protein and nucleotide sequencing of the paraproteins' variable regions revealed 2 predominant Vl
48                               The median IgM paraprotein was 8 g/L and serum free light chain (FLC) r
49              An immunoglobulin M (IgM) kappa paraprotein was detected in 86%; the remainder had IgM l
50   Stable disease (less than 25% reduction in paraprotein) was observed in an additional 2 (8%) patien
51 and reduction in levels of circulating human paraprotein were observed in mice treated with B-B4-DM1.
52                 The serum or urine levels of paraprotein were reduced by at least 90 percent in eight
53  and in four of these cases at least two IgM paraproteins were present.
54 vious efforts to reconstruct the epitopes of paraproteins, with the significant difference that it pr

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。